This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Rx-to-OTC Switches Market

Market Insights on Rx-to-OTC Switches covering sales outlook, demand forecast & up-to-date key trends

Rx to OTC Switch Market by Drug Category (Allergy and Respiratory, Fungal Infections & Other Infections, Overactive Bladder, Oral Contraceptives, Gastrointestinal Drugs, Hair Loss Treatments), Distribution Channel & Region - Forecast to 2021-2031

Rx-to-OTC Switches Market Snapshot

Rx-to-OTC switches sales value is estimated to total US$ 35 Bn in 2021, according to a Future Market Insights (FMI) study. Exhibiting 5.3% CAGR, the overall Rx-to-OTC switches market size is likely to surpass US$ 58 Bn by 2031.

Despite a period of tepid sales, growth will recover at a year on year rate of 5.2% in 2021. The demand for allergy and respiratory drugs is expected to increase at an accelerated pace in the coming decade. As per FMI analysis, allergy and respiratory drugs segment will account for 26.7% of the Rx-to-OTC switches market in 2021.

Customize this Report

Let us know your requirement to get
100% FREE customization

Key Points Covered in Rx-to-OTC Switches Market Study

  • Market estimates and forecast 2016-2031
  • Key drivers and restraints impacting market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Brand share and Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Rx-to-OTC Switches Market and How to Navigate
  • Recommendation on Key Winning Strategies

2016-2020 Rx-to-OTC Switches Market Outlook Compared to 2021-2031 Forecast

According to Future Market Insights (FMI), the sales of Rx-to-OTC switched products have grown at a 1.5% CAGR between 2016 and 2020. Rx-to-OTC switch products are the transition of proven prescription drugs to nonprescription, over-the-counter (OTC) status. It is a strict and highly regulated process that allows consumers to gain OTC access to a growing range of medicines for treating common diseases like headache, cold and flu, and cough, among others.

Rx to OTC switch is gaining popularity as one of the best ways to provide cost-effective, first-line treatment for common illnesses like cough, cold, flu, and headache.  Many patients do not have time to visit the doctors or the physicians they mainly prefer quick access to OTC medicines.

As OTC products are widely available in pharmacies, the delayed physician supervision has lowered the demand for prescription drugs to treat common diseases. Considerably, the rising demand for OTC over prescription products has led many pharmaceutical companies to assume that the switches would contribute significantly to OTC revenue growth in the near future.

Key markets such as the U.S., India, and China, have significant untapped potential for the expansion of Rx-to-OTC switches market. Growth in research and development (R&D) capabilities to meet the global demand for OTC medicines over the prescription will aid the expansion of the market. Small and large pharmaceutical companies are focusing on the Rx to OTC switch owing to the rising OTC demand over prescription drugs.

Rx-to-OTC Switches Market Download Report Brochure

Various safety studies are undertaken to comply with Food and Drug Administration (FDA) requirements, which are intended to improve efficacy and safety of drug available over the counter. These regulations will also help in preventing misuse and abuse of OTC drugs.

After a long period of drought in the year 2018 and 2019, in 2020 FDA approved three Rx-to-OTC switch produts including Pataday Twice Daily Relief (ophthalmic solution/drops), Voltaren Arthritis Pain (topical gel), and Pataday Once Daily Relief (ophthalmic solution/drops) for OTC use. Such approvals will continue aiding growth in the market.

Future Market Insights forecasts the global Rx-to-OTC switches market to rise at 5.3 % CAGR between 2021 and 2031.

What are the Leading Opportunities for Market Growth?

Patient compatibility and safety for self-medication are key concerns among pharmaceutical companies. Manufacturers are focusing on patient centricity to ensure long-term success by offering safety and high potential products that will attract consumers. They are exploring opportunities for manufacturers in the market.

The past decade has witnessed a decline in Rx-to-OTC switches with only one switch, including 2010, 2011, and 2015 and zero switches in the year 2018 and 2019. While in 2020 there was increase in the switches owing to the growing demand for OTC products which is expected to continue in 2021.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How will Regulations on Healthcare Sector Impact Rx-to-OTC Switches?

The regulatory burden associated with multiple clearance procedures under FDA’s scientific decisions to a nimble “administrative order” process within agencies, speeding up decisions considerably, is key to requisite infrastructure.

OTC products should demonstrate an adequate safety and efficacy profile to meet the FDA’s approval standards. Evidence of safety, correct diagnosis, and treatment of medical conditions with minimal professional supervision makes the approval process complicated.

This creates hesitatance among pharmaceutical companies to invest in the switch market, impeding the growth of the Rx-to-OTC switches market.

For instance, Mevacor® (a cholesterol-lowering statin drug) and Pravachol®(a statin medication), both failed to obtain approval for an Rx-to-OTC switch due to the FDA’s conclusion that patients’ perceptions of their disease and the monitoring necessary for successful disease management were not adequately understood and demonstrated.

Additionally, The COVID-19 pandemic caused a shift in behaviours relating to both prescription and OTC medicines owing to the ease of drug use habits and availability. Although OTC drugs are less potent than other substances, they still pose a risk of addiction. Lack of awareness can cause incorrect self-diagnosis, complications, and associated adverse effects.

What is the Impact of the COVID-19 Crisis on Rx-to-OTC Switches Sales?

The OTC consumer health sector has been a key focus of pharmaceutical companies recently, especially after the pandemic arrived in 2020. In 2020, numerous prescription (Rx) medicines switched to OTC status. These include pharmaceutical companies such as GlaxoSmithKline plc, Alcon Laboratories Inc. and some Asian pharmaceutical companies including  Lupin and Cipla.

After a long period of wait, FDA approved the Rx-to-OTC switch of 3 prescription products. With the Covid-19 pandemic intensifying, it is expected that the focus on OTC products will continue to strengthen because visits to doctors are restricted.

Consequently, the sales of Rx to OTC switch products was seen to increase in 2020. There was a positive impact on market growth which is expected to drive sales across the forecast period as well.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Country-wise Insights

How Lucrative is the Opportunity for Manufacturers in the U.S?

The U.S. holds over 75% share of the Rx-to-OTC switches market in North America. In the U.S., the research collaboration and approvals for prescription switched drugs are key to market developments.

Based on recent switches, the FDA seems to follow a more conservative path in approving traditional types of OTC products used for self-limiting, acute, non-life-threatening conditions with readily recognizable symptoms that consumers can identify. However, the FDA tends to approve products for preventing chronic conditions like asthma or heart disease.

Moreover, after a long period of decline in approvals, in 2020, FDA approved the Rx-to-OTC switch of three prescription drugs. However, expansion strategies implemented by pharmaceutical companies seeking approval is progress towards providing consumers access to an effective treatment.

For instance, In February 2020, GSK received FDA approval for Voltaren Arthritis Pain as an OTC product to temporarily relieve arthritis pain, which is commercially available in the U.S.

What are the Favorable Policies Driving Growth of Rx-to-OTC Switches in the U.K.?

The U.K. market will account for over 33% of the Europe market through the assessment period ending in 2031. The U.K. Pharmacy Minister Earl Howe has continually stressed that considering the patient's demand for access of ease of availability, medicines without a prescription is a priority for the British government.

Outside the regulatory systems of the EU, the MHRA is focusing on exploring different pathways to Rx-to-OTC switches.Currently, the UK government is focusing on reviewing plans for all opioid-containing medicines sold in the country to carry on-pack addiction warnings which is manipulating the demand for OTC products.

What are the Key Factors Enabling Growth in Germany?

The Germany market will exhibit a 5.0% CAGR throughout the forecast period. Regulatory guidelines are relatively strict in Germany. As a result, achieving drug approvals for Rx-OTC switch assistance is a complex procedure in the country. Germany is the second leading market in Europe due to the presence of leading manufacturers enhancing the R&D capabilities.

For instance, Merck Co. Ltd. A German-based pharmaceutical company invested around €18 million at its site in Tempe, Arizona located U.S. This investment would provide flexibility to invest in its production facilities and strengthen its R&D capabilities in its global network.

What is the Scope of growth of Rx-to-OTC Switches Sales in the India Market?

The Indian market accounted for more than 33% of the sales registered in the South Asia region in 2021. India ranks as the 11th largest OTC drug market globally and is counted amongst one of the most lucrative markets globally. Indian pharma companies have a significant edge over their counterparts, influenced by the consumer’s needs.

The Indian pharma companies are shifting their focus to a less-explored market, i.e. OTC drugs to reduce dependency on other countries for APIs and raw materials. Recent developments have given rise to new buying trends. Consumer preference towards Made in India tagged drugs are expected to flourish in the post-pandemic era.

Thus increasing disposable income along with a shift in consumer attitude toward the cost-effectiveness- in self-medication has significantly propelled the demand for Rx-to-OTC switches in the country.

What are the Factors Driving Revenue Generation in the China market?

The market for Rx-to-OTC switches in China is exhibiting 8.0% CAGR and is expected to account for more than 45% of the East Asia market throughout the projection period. Large emerging markets, especially in China have a great opportunity in expansion towards Rx-to-OTC switches.

As China has no market exclusivity for R&D capacity of Rx-to-OTC switches, any leading pharmaceutical company can manufacture and commercialize in the region once the switch sponsor has received approval from the SFDA.

Category-wise Insights

How are Allergy and Respiratory Drugs Contributing to Revenue?

Allergy and respiratory drugs have a higher potential for growth in the coming years. The segment is likely to grow with a high CAGR of 5.7% in the coming decade. Antihistamines are the first approved Rx-to-OTC switched drugs that have the potential to treat lifestyle-based ailments and has gained popularity in the market. For example, OTC antihistamine eye drops relieve red itchy eyes, while nasal sprays can be used to treat the symptoms of seasonal or year-round allergies.

What is the Scope of Growth for Retail Pharmacies in the Market?

Retail pharmacies are currently leading the market, with significant growth in the Rx-to-OTC Switches market with a 5.1% CAGR in the forecast period. Retail pharmacies have made possible the availability of OTC drugs to treat numerous ailments without healthcare professional in high stocks and cost-effective prices. Pharmacists played a vital role in controlling the number of medications being dispensed as OTC drugs.

Competitive Landscape

Participants in the Rx-to-OTC switches market are primarily aiming for strategic collaborations and R&D investments to consolidate growth in a competitive and fragmented market. With this, pharmaceutical companies are also engaged in expanding their global and regional presence through acquisitions, expansions, product launches and improvement of distribution channels to penetrate the new regional markets.

  • For Instance, In April 2021, Pfizer Inc. acquired Amplyx Pharmaceuticals, Inc., a privately-held pharmaceutical company.
  • In June 2021, FDA approved Rx-to-OTC switch for Astepro allergy nasal spray, which will be liableble at mass retail locations across the U.S.
  • In January 2021, Viagra will be available to consumers in Ireland via OTC channels following a successful switch procedure, with a simple pharmacist consultation.

Scope of the Report

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

USD Million for Value in Million

Key Countries Covered

US, Canada, U.K.,  Germany, Italy, France, Spain, Benelux, Russia,  India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, Turkey, South Africa and North Africa

Key Segments Covered

Drug Category, Distribution Channel, and Region

Key Companies Profiled

  • GlaxoSmithKline plc.
  • Astrazeneca, Merck KGaA
  • Johnson & Johnson
  • Bayer AG
  • Sanofi
  • Boehringer Ingelheim Consumer Healthcare
  • Bausch and Lomb (A Subsidiary of Bausch Health)
  • Galderma SA
  • Alcon
  • Arbor Pharmaceuticals

Report Coverage

Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Rx to OTC Switch Market by Category

Drug Category

  • Allergy and Respiratory
  • Fungal Infections & Other Infections
  • Overactive Bladder
  • Oral Contraceptives
  • Gastrointestinal Drugs
  • Hair Loss Treatments
  • Smoking Cessation
  • Analgesic, Inflammation And Pain Management
  • Others (Lice, Acne, Weight Loss, And Laxative)

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

The Rx-to-OTC switches market will be worth US$ 35 Bn in the year 2021 and is expected to reach US$ 58 Bn by 2031 owing to growing demand for OTC over prescribed drugs.

Response: The Rx-to-OTC switches market is estimated to grow at a CAGR of 5.3% during the forecast period with an estimated Rx-to-OTC switched products revenue accounting more than US$ 58 Bn in 2031.

Historically, the market has grown at a CAGR of 1.5% in the last 5 years, between 2016 and 2020.

Altering the dosage form of the prescribed drugs to extend its life-cycle, offering patient centric products with increased customization, higher approval for the modified products to treat new indications, and adoption of strategic agreements by key market leaders are some of the key trends adopted by the manufacturers.

Growing preference for OTC drugs over prescribed drugs, rising demand for accessible and varied treatment options, are some of the driving factors that has bolstered the demand in the market.

The cumulative market share of top 3 players including GlaxoSmithKline Plc, Sanofi, and Johnson & Johnson constitute over 46% of the overall market.

The U.S., U.K., Germany, China, and India are the top 5 countries that are driving the demand for Rx-to-OTC switches market.

North America holds more than 26% revenue share in the overall Rx-to-OTC switches market in 2021. Rising approvals and presence of key players in the market are driving the demand for Rx-to-OTC switches in the region.

The Europe market is set to exhibit a CAGR of 4.7% during the forecast period.

The U.S., India, Germany, U.K. and China are some of the key producers in the Rx-to-OTC switches market.

GlaxoSmithKline Plc., Sanofi, Johnson & Johnson, Pfizer Inc., AstraZeneca, Merck KGaA , and Bayer AG are some of the key exporters of the Rx-to-OTC switches market.

Japan has emerged as a key market, exhibiting growth at 6.7% during the forecast period. South Korea will account for 16.8% of the East Asia Rx-to-OTC switches market in 2021.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

4. Market Background

    4.1. Macro-Economic Factors

        4.1.1. Global GDP Growth Outlook

        4.1.2. Global Healthcare Outlook

        4.1.3. Per Capita Healthcare Expenditure Outlook

    4.2. Forecast Factors - Relevance & Impact

        4.2.1. Growing Demand and Sales for OTC Medication  

        4.2.2. Cost of OTC Medication 

        4.2.3. Availability of OTC Drugs 

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity Analysis

5. COVID19 Crisis Analysis

    5.1. Current COVID19 Probable Future Impact

    5.2. Current GDP Projection and Probable Impact

    5.3. Current Economic Projection as compared to 2008 Economic analysis

    5.4. COVID19 and Impact Analysis

            5.4.1.1. Revenue By  Drug Categories

            5.4.1.2. Revenue By Distribution Channel 

            5.4.1.3. Revenue By Region

    5.5. 2020 Market Scenario

    5.6. Recovery Scenario – Short term, Midterm and Long Term Impact

6. Key Success Factors

    6.1. Business Model

    6.2. Key Regulations

    6.3. Go-To-Market Strategy

    6.4. Adoption Rate of OTC drugs, By Region 

7. Global Rx-to-OTC Switches Market Demand (in US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031

    7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020

    7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031, by Drug Category  

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Drug Category, 2016–2020

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Category, 2021-2031

        8.3.1. Allergy and Respiratory

        8.3.2. Fungal Infections & Other infections

        8.3.3. Overactive Bladder 

        8.3.4. Oral Contraceptives 

        8.3.5. Gastrointestinal Drugs 

        8.3.6. Hair Loss Treatments 

        8.3.7. Smoking Cessation 

        8.3.8. Analgesic, Inflammation and pain management

        8.3.9. Others (lice, Acne, weight loss, laxative)

    8.4. Market Attractiveness Analysis By Drug Category

9. Global Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031, by Distribution Channel 

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016–2020

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031

        9.3.1. Retail Pharmacies

        9.3.2. Hospital Pharmacies

        9.3.3. Drug Stores

        9.3.4. Online Pharmacies

    9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031, by Region

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016–2020

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. South Asia

        10.3.5. East Asia

        10.3.6. Oceania

        10.3.7. Middle East & Africa 

    10.4. Market Attractiveness Analysis By Region

11. North America Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031

        11.3.1.  By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Drug Category 

        11.3.3. By Distribution Channel  

    11.4. Market Attractiveness Analysis

    11.5. Key Market Participants - Intensity Mapping

    11.6. Drivers and Restraints - Impact Analysis

12. Latin America Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031

        12.3.1.  By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Drug Category 

        12.3.3. By Distribution Channel

    12.4. Market Attractiveness Analysis

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

13. Europe Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By Drug Category 

        13.3.3. By Distribution Channel 

    13.4. Market Attractiveness Analysis

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. East Asia Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    14.3. Current and Future Market Size (US$ Mn) Trend and  Analysis and Forecast By Market Taxonomy, 2021-2031

        14.3.1. By Country

            14.3.1.1. China

            14.3.1.2. Japan

            14.3.1.3. South Korea

        14.3.2. By Drug Category 

        14.3.3. By Distribution Channel 

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. South Asia Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Thailand

            15.3.1.3. Indonesia

            15.3.1.4. Malaysia

            15.3.1.5. Rest of South Asia

        15.3.2. By Drug Category 

        15.3.3. By Distribution Channel  

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Oceania Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031

        16.3.1.  By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Drug Category 

        16.3.3. By Distribution Channel 

    16.4. Market Attractiveness Analysis

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. Turkey

            17.3.1.3. Northern Africa

            17.3.1.4. South Africa

            17.3.1.5. Rest of Middle East and Africa

        17.3.2. By Drug Category 

        17.3.3. By Distribution Channel 

    17.4. Market Attractiveness Analysis

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

18. Key and Emerging Countries Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031

    18.1. Introduction

        18.1.1. Market Value Proportion Analysis, By Key Countries

        18.1.2. Global Vs. Country Growth Comparison

    18.2. U.S. Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031

        18.2.1. By Drug Category 

        18.2.2. By Distribution Channel

    18.3. Canada Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031

        18.3.1. By Drug Category

        18.3.2. By Distribution Channel

    18.4. Mexico Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031

        18.4.1. By Drug Category

        18.4.2. By Distribution Channel

    18.5. Brazil Rx-to-OTC Switches Market Value (US$)  Analysis, 2021 & 2031

        18.5.1. By Drug Category 

        18.5.2. By Distribution Channel

    18.6. U.K. Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031

        18.6.1. By Drug Category 

        18.6.2. By Distribution Channel

    18.7. Germany Rx-to-OTC Switches Market Analysis

        18.7.1. By Drug Category 

        18.7.2. By Distribution Channel

    18.8. France Rx-to-OTC Switches Market Analysis

        18.8.1. By Drug Category 

        18.8.2. By Distribution Channel 

    18.9. Italy Rx-to-OTC Switches Market Analysis

        18.9.1. By Drug Category 

        18.9.2. By Distribution Channel 

    18.10. Spain Rx-to-OTC Switches Market Analysis

        18.10.1. By Drug Category 

        18.10.2. By Distribution Channel

    18.11. Russia Rx-to-OTC Switches Market Analysis

        18.11.1. By Drug Category 

        18.11.2. By Distribution Channel

    18.12. China Rx-to-OTC Switches Market Analysis

        18.12.1. By Drug Category 

        18.12.2. By Distribution Channel  

    18.13. Japan Rx-to-OTC Switches Market Analysis

        18.13.1. By Drug Category 

        18.13.2. By Distribution Channel 

    18.14. South Korea Rx-to-OTC Switches Market Analysis

        18.14.1. By Drug Category

        18.14.2. By Distribution Channel

    18.15. India Rx-to-OTC Switches Market Analysis

        18.15.1. By Drug Category 

        18.15.2. By Distribution Channel

    18.16. Thailand Rx-to-OTC Switches Market Analysis

        18.16.1. By Drug Category 

        18.16.2. By Distribution Channel

    18.17. Indonesia Rx-to-OTC Switches Market Analysis

        18.17.1. By Drug Category 

        18.17.2. By Distribution Channel

    18.18. Malaysia Rx-to-OTC Switches Market Analysis

        18.18.1. By Drug Category 

        18.18.2. By Distribution Channel

    18.19. Australia Rx-to-OTC Switches Market Analysis

        18.19.1. By Drug Category

        18.19.2. By Distribution Channel

    18.20. New Zealand Rx-to-OTC Switches Market Analysis

        18.20.1. By Drug Category 

        18.20.2. By Distribution Channel 

    18.21. GCC Countries Rx-to-OTC Switches Market Analysis

        18.21.1. By Drug Category  

        18.21.2. By Distribution Channel

    18.22. South Africa Rx-to-OTC Switches Market Analysis

        18.22.1. By Drug Category

        18.22.2. By Distribution Channel

    18.23. Turkey Rx-to-OTC Switches Market Analysis

        18.23.1. By Drug Category

        18.23.2. By Distribution Channel

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies 

    19.2. Market Share Analysis of Top Players

    19.3. Market Concentration

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Deep Dive 

        20.2.1. GlaxoSmithKline plc. 

            20.2.1.1. Overview

            20.2.1.2. Product Portfolio

            20.2.1.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.1.4. Sales Footprint

            20.2.1.5. Strategy Overview

                20.2.1.5.1. Marketing Strategy

                20.2.1.5.2. Product Strategy

                20.2.1.5.3. Channel Strategy

        20.2.2. Astrazeneca

            20.2.2.1. Overview

            20.2.2.2. Product Portfolio

            20.2.2.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.2.4. Sales Footprint

            20.2.2.5. Strategy Overview

                20.2.2.5.1. Marketing Strategy

                20.2.2.5.2. Product Strategy

                20.2.2.5.3. Channel Strategy

        20.2.3. Merck KGaA

            20.2.3.1. Overview

            20.2.3.2. Product Portfolio

            20.2.3.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.3.4. Sales Footprint

            20.2.3.5. Strategy Overview

                20.2.3.5.1. Marketing Strategy

                20.2.3.5.2. Product Strategy

                20.2.3.5.3. Channel Strategy

        20.2.4. Johnson & Johnson

            20.2.4.1. Overview

            20.2.4.2. Product Portfolio

            20.2.4.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.4.4. Sales Footprint

            20.2.4.5. Strategy Overview

                20.2.4.5.1. Marketing Strategy

                20.2.4.5.2. Product Strategy

                20.2.4.5.3. Channel Strategy

        20.2.5. Bayer AG

            20.2.5.1. Overview

            20.2.5.2. Product Portfolio

            20.2.5.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.5.4. Sales Footprint

            20.2.5.5. Strategy Overview

                20.2.5.5.1. Marketing Strategy

                20.2.5.5.2. Product Strategy

                20.2.5.5.3. Channel Strategy

        20.2.6. Sanofi

            20.2.6.1. Overview

            20.2.6.2. Product Portfolio

            20.2.6.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.6.4. Sales Footprint

            20.2.6.5. Strategy Overview

                20.2.6.5.1. Marketing Strategy

                20.2.6.5.2. Product Strategy

                20.2.6.5.3. Channel Strategy

        20.2.7. Boehringer Ingelheim Consumer Healthcare

            20.2.7.1. Overview

            20.2.7.2. Product Portfolio

            20.2.7.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.7.4. Sales Footprint

            20.2.7.5. Strategy Overview

                20.2.7.5.1. Marketing Strategy

                20.2.7.5.2. Product Strategy

                20.2.7.5.3. Channel Strategy

        20.2.8. Bausch and Lomb (A Subsidiary of Bausch Health)

            20.2.8.1. Overview

            20.2.8.2. Product Portfolio

            20.2.8.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.8.4. Sales Footprint

            20.2.8.5. Strategy Overview

                20.2.8.5.1. Marketing Strategy

                20.2.8.5.2. Product Strategy

                20.2.8.5.3. Channel Strategy

        20.2.9. Galderma SA

            20.2.9.1. Overview

            20.2.9.2. Product Portfolio

            20.2.9.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.9.4. Sales Footprint

            20.2.9.5. Strategy Overview

                20.2.9.5.1. Marketing Strategy

                20.2.9.5.2. Product Strategy

                20.2.9.5.3. Channel Strategy

        20.2.10. Alcon

            20.2.10.1. Overview

            20.2.10.2. Product Portfolio

            20.2.10.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.10.4. Sales Footprint

            20.2.10.5. Strategy Overview

                20.2.10.5.1. Marketing Strategy

                20.2.10.5.2. Product Strategy

                20.2.10.5.3. Channel Strategy

        20.2.11. Arbor Pharmaceuticals

            20.2.11.1. Overview

            20.2.11.2. Product Portfolio

            20.2.11.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.11.4. Sales Footprint

            20.2.11.5. Strategy Overview

                20.2.11.5.1. Marketing Strategy

                20.2.11.5.2. Product Strategy

                20.2.11.5.3. Channel Strategy 

21. Assumptions and Acronyms Used 

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Category

Table 02: Global Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 03: Global Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Region

Table 04: North America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 05: North America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category

Table 06: North America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Distribution Channel

Table 07: Latin America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 08: Latin America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category

Table 09: Latin America Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 10: Europe Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 11: Europe Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category

Table 12: Europe Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 13: East Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 14: East Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category

Table 15: East Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 16: South Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 17: South Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category

Table 18: South Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 19: Oceania Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 20: Oceania Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category

Table 21: Oceania Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Table 22: Middle East & Africa Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country

Table 23: Middle East & Africa Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category

Table 24: Middle East & Africa Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Rx-to-OTC Switches Market size (US$ Mn) 2021E & 2031F

Figure 02: Global Rx-to-OTC Switches Market Value Share, by Drug Category 2020 (A)

Figure 03: Global Rx-to-OTC Switches Market Value Share, by Distribution Channel 2020 (A)

Figure 04: Global Rx-to-OTC Switches Market Value Share, by Region 2020 (A)

Figure 05: Global Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020

Figure 06: Global Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021 - 2031

Figure 07: Global Rx-to-OTC Switches Market Absolute $ Opportunity, 2021 - 2031

Figure 08: Global Rx-to-OTC Switches Market Share Analysis (%), By Drug Category, 2021& 2031

Figure 09: Global Rx-to-OTC Switches Market Y-o-Y Analysis (%), By Drug Category, 2021- 2031

Figure 10: Global Rx-to-OTC Switches Market Attractiveness Analysis By Drug Category, 2021 & 2031

Figure 11: Global Rx-to-OTC Switches Market Share Analysis (%), By Distribution Channel, 2021& 2031

Figure 12: Global Rx-to-OTC Switches Market Y-o-Y Analysis (%), By Distribution Channel, 2021 - 2031

Figure 13: Global Rx-to-OTC Switches Market Attractiveness Analysis By Distribution Channel, 2021& 2031

Figure 14: Global Rx-to-OTC Switches Market Share Analysis (%), By Country, 2021& 2031

Figure 15: Global Rx-to-OTC Switches Market Y-o-Y Analysis (%), By Country, 2021& 2031

Figure 16: Global Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021- 2031

Figure 17: North America Rx-to-OTC Switches Market Value Share By Drug Category 2021 (E)

Figure 18: North America Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)

Figure 19: North America Rx-to-OTC Switches Market Value Share By Country 2021 (E)

Figure 20: North America Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020

Figure 21: North America Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021- 2031

Figure 22: North America Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021 -2031

Figure 23: North America Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 24: North America Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021 - 2031

Figure 25: Latin America Rx-to-OTC Switches Market Value Share By Application 2021 (E)

Figure 26: Latin America Rx-to-OTC Switches Market Share By Distribution Channel 2021 (E)

Figure 27: Latin America Rx-to-OTC Switches Market Value Share By Country 2021 (E)

Figure 28: Latin America Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020

Figure 29: Latin America Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021 & 2031

Figure 30: Latin America Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021 - 2031

Figure 31: Latin America Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 32: Latin America Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021 - 2031

Figure 33: Europe Rx-to-OTC Switches Market Value Share, By Drug Category 2021 (E)

Figure 34: Europe Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)

Figure 35: Europe Rx-to-OTC Switches Market Value Share By Country 2021 (E)

Figure 36: Europe Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020

Figure 37: Europe Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021 & 2031

Figure 38: Europe Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021 - 2031

Figure 39: Europe Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 40: Europe Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021 - 2031

Figure 41: East Asia Rx-to-OTC Switches Market Value Share, By Drug Category 2021 (E)

Figure 42: East Asia Rx-to-OTC Switches Market Value Share, By Distribution Channel 2021 (E)

Figure 43: East Asia Rx-to-OTC Switches Market Value Share, By Country 2021 (E)

Figure 44: East Asia Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020

Figure 45: East Asia Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021 -2031

Figure 46: East Asia Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021-2031

Figure 47: East Asia Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 48: East Asia Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021-2031

Figure 49: South Asia Rx-to-OTC Switches Market Value Share By Drug Category 2021 (E)

Figure 50: South Asia Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)

Figure 51: South Asia Rx-to-OTC Switches Market Value Share By Country 2021 (E)

Figure 52: South Asia Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020

Figure 53: South Asia Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021& 2031

Figure 54: South Asia Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021-2031

Figure 55: South Asia Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 56: South Asia Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021-2031

Figure 57: Oceania Rx-to-OTC Switches Market Value Share By Drug Category 2021 (E)

Figure 58: Oceania Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)

Figure 59: Oceania Rx-to-OTC Switches Market Value (US$ Mn) & Forecast 2021& 2031

Figure 60: Oceania Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020

Figure 61: Oceania Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021& 2031

Figure 62: Oceania Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021-2031

Figure 63: Oceania Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 64: Oceania Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021-2031

Figure 65: Middle East & Africa Rx-to-OTC Switches Market Value Share By Drug Category 2021 (E)

Figure 66: Middle East & Africa Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)

Figure 67: Middle East & Africa Rx-to-OTC Switches Market Value Share By Country 2021 (E)

Figure 68: Middle East & Africa Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020

Figure 69: Middle East & Africa Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021& 2031

Figure 70: Middle East & Africa Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021-2031

Figure 71: Middle East & Africa Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021-2031

Figure 72: Middle East & Africa Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021-2031

Figure 73: Global Rx-to-OTC Switches Market Value Proportion Analysis, By Key Countries, 2021 (E)

Figure 74: Rx-to-OTC Switches Market , Global Vs. Country Growth Y-o-Y (%) Comparison, 2021-2031

Figure 75: U.S. Market Value Proportion Analysis

Figure 76: Global Vs U.S. Growth Comparison

Figure 77: U.S. Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 78: U.S. Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 79: Canada Market Value Proportion Analysis

Figure 80: Global Vs Canada Growth Comparison

Figure 81: Canada Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 82: Canada Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 83: Mexico Market Value Proportion Analysis

Figure 84: Global Vs Mexico Growth Comparison

Figure 85: Mexico Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 86: Mexico Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 87: Brazil Market Value Proportion Analysis

Figure 88: Global Vs Brazil Growth Comparison

Figure 89: Brazil Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 90: Brazil Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 91: U.K. Market Value Proportion Analysis

Figure 92: Global Vs U.K. Growth Comparison

Figure 93: U.K. Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 94: U.K. Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 95: Germany Market Value Proportion Analysis

Figure 96: Global Vs Germany Growth Comparison

Figure 97: Germany Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 98: Germany Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 99: France Market Value Proportion Analysis

Figure 100: Global Vs France Growth Comparison

Figure 101: France Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 102: France Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 103: Italy Market Value Proportion Analysis

Figure 104: Global Vs Italy Growth Comparison

Figure 105: Italy Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 106: Italy Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 107: Spain Market Value Proportion Analysis

Figure 108: Global Vs Spain Growth Comparison

Figure 109: Spain Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 110: Spain Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 111: Russia Market Value Proportion Analysis

Figure 112: Global Vs Russia Growth Comparison

Figure 113: Russia Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 114: Russia Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 115: China Market Value Proportion Analysis

Figure 116: Global Vs China Growth Comparison

Figure 117: China Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 118: China Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 119: Japan Market Value Proportion Analysis

Figure 120: Global Vs Japan Growth Comparison

Figure 121: Japan Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 122: Japan Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 123: South Korea Market Value Proportion Analysis

Figure 124: Global Vs South Korea Growth Comparison

Figure 125: South Korea Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 126: South Korea Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 127: India Market Value Proportion Analysis

Figure 128: Global Vs India Growth Comparison

Figure 129: India Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 130: India Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 131: Thailand Market Value Proportion Analysis

Figure 132: Global Vs Thailand Growth Comparison

Figure 133: Thailand Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 134: Thailand Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 135: Indonesia Market Value Proportion Analysis

Figure 136: Global Vs Indonesia Growth Comparison

Figure 137: Indonesia Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 138: Indonesia Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 139: Malaysia Market Value Proportion Analysis

Figure 140: Global Vs Malaysia Growth Comparison

Figure 141: Malaysia Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 142: Malaysia Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 143: Australia Market Value Proportion Analysis

Figure 144: Global Vs Australia Growth Comparison

Figure 145: Australia Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 146: Australia Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 147: New Zealand Market Value Proportion Analysis

Figure 148: Global Vs New Zealand Growth Comparison

Figure 149: New Zealand Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 150: New Zealand Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 151: GCC Countries Market Value Proportion Analysis

Figure 152: Global Vs GCC Countries Growth Comparison

Figure 153: GCC Countries Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 154: GCC Countries Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 155: South Africa Market Value Proportion Analysis

Figure 156: Global Vs South Africa Growth Comparison

Figure 157: South Africa Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 158: South Africa Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Figure 159: Turkey Market Value Proportion Analysis

Figure 160: Global Vs Turkey Growth Comparison

Figure 161: Turkey Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031

Figure 162: Turkey Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Rx-to-OTC Switches Market